131 related articles for article (PubMed ID: 2947964)
1. Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer.
Walker KJ; Turkes A; Williams MR; Blamey RW; Nicholson RI
J Endocrinol; 1986 Nov; 111(2):349-53. PubMed ID: 2947964
[TBL] [Abstract][Full Text] [Related]
2. Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer.
Walker KJ; Walker RF; Turkes A; Robertson JF; Blamey RW; Griffiths K; Nicholson RI
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):651-4. PubMed ID: 2523808
[TBL] [Abstract][Full Text] [Related]
3. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer.
Nicholson RI; Walker KJ; Turkes A; Dyas J; Plowman PN; Williams M; Blamey RW
J Steroid Biochem; 1985 Nov; 23(5B):843-7. PubMed ID: 2934580
[TBL] [Abstract][Full Text] [Related]
4. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
[TBL] [Abstract][Full Text] [Related]
5. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
[TBL] [Abstract][Full Text] [Related]
6. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
Robertson JF; Walker KJ; Nicholson RI; Blamey RW
Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
[TBL] [Abstract][Full Text] [Related]
7. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study).
Bianco AR; Rosso R; Calabresi F; Fiorentino M; Lopez M; Sismondi PG; Lenti R; Fosser V; De Placido S; Perrone F
Eur J Gynaecol Oncol; 1991; 12(6):429-37. PubMed ID: 1839730
[TBL] [Abstract][Full Text] [Related]
8. Goserelin depot in the treatment of premenopausal advanced breast cancer.
Blamey RW; Jonat W; Kaufmann M; Bianco AR; Namer M
Eur J Cancer; 1992; 28A(4-5):810-4. PubMed ID: 1388037
[TBL] [Abstract][Full Text] [Related]
9. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue.
West CP; Baird DT
Clin Endocrinol (Oxf); 1987 Feb; 26(2):213-20. PubMed ID: 2959405
[TBL] [Abstract][Full Text] [Related]
10. Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women.
Matta WH; Shaw RW; Burford GD
Fertil Steril; 1988 Jan; 49(1):163-5. PubMed ID: 2961621
[TBL] [Abstract][Full Text] [Related]
11. The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer--a 5-year experience and further endocrine therapies. Cooperative German Zoladex Study Group.
Kaufmann M; Jonat W; Schachner-Wünschmann E; Bastert G; Maass H
Onkologie; 1991 Feb; 14(1):22-4, 26-8, 30. PubMed ID: 1829149
[TBL] [Abstract][Full Text] [Related]
12. Medical castration with zoladex: a conservative approach to premenopausal breast cancer.
Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M; Bonadonna G
Tumori; 1991 Apr; 77(2):145-50. PubMed ID: 1828640
[TBL] [Abstract][Full Text] [Related]
13. Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.
Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M
Anticancer Drugs; 1992 Feb; 3(1):3-8. PubMed ID: 1535804
[TBL] [Abstract][Full Text] [Related]
14. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
Plowman PN; Nicholson RI; Walker KJ
Br J Cancer; 1986 Dec; 54(6):903-9. PubMed ID: 2948537
[TBL] [Abstract][Full Text] [Related]
15. Effects of bovine follicular fluid on gonadotrophin secretion in intact and chronically ovariectomized ewes before and after desensitization of pituitary gonadotrophs to gonadotrophin-releasing hormone.
Knight PG; Castillo RJ
J Endocrinol; 1988 Jun; 117(3):431-9. PubMed ID: 2969030
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer.
Nicholson RI; Walker KJ; Turkes A; Turkes AO; Dyas J; Blamey RW; Campbell FC; Robinson MR; Griffiths K
J Steroid Biochem; 1984 Jan; 20(1):129-35. PubMed ID: 6231416
[TBL] [Abstract][Full Text] [Related]
17. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
Reyes FI; Winter JS; Faiman C
Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
[TBL] [Abstract][Full Text] [Related]
18. Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer.
Falkson CI; Falkson HC; Falkson G
Eur J Cancer; 1991; 27(10):1208-11. PubMed ID: 1835587
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
[TBL] [Abstract][Full Text] [Related]
20. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
